The role of mTOR inhibition as second-line therapy in metastatic renal carcinoma: clinical evidence and current challenges
出版年份 2017 全文链接
标题
The role of mTOR inhibition as second-line therapy in metastatic renal carcinoma: clinical evidence and current challenges
作者
关键词
-
出版物
Expert Review of Anticancer Therapy
Volume 17, Issue 3, Pages 217-226
出版商
Informa UK Limited
发表日期
2017-01-20
DOI
10.1080/14737140.2017.1273774
参考文献
相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。- Updated EAU Guidelines for Clear Cell Renal Cancer Patients Who Fail VEGF Targeted Therapy
- (2016) Thomas Powles et al. EUROPEAN UROLOGY
- Cabozantinib versus everolimus in advanced renal cell carcinoma (METEOR): final results from a randomised, open-label, phase 3 trial
- (2016) Toni K Choueiri et al. LANCET ONCOLOGY
- Everolimus in metastatic renal cell carcinoma after failure of initial anti–VEGF therapy: final results of a noninterventional study
- (2015) Lothar Bergmann et al. BMC CANCER
- Everolimus and Temsirolimus Are Not the Same Second-Line in Metastatic Renal Cell Carcinoma. A Systematic Review and Meta-Analysis of Literature Data
- (2015) Roberto Iacovelli et al. Clinical Genitourinary Cancer
- Everolimus for patients with metastatic renal cell carcinoma refractory to anti-VEGF therapy: Results of a pooled analysis of non-interventional studies
- (2015) Laurence Albiges et al. EUROPEAN JOURNAL OF CANCER
- SWITCH: A Randomised, Sequential, Open-label Study to Evaluate the Efficacy and Safety of Sorafenib-sunitinib Versus Sunitinib-sorafenib in the Treatment of Metastatic Renal Cell Cancer
- (2015) Christian Eichelberg et al. EUROPEAN UROLOGY
- Prognostic factors for survival following initiation of second-line treatment with everolimus for metastatic renal cell carcinoma: evidence from a nationwide sample of clinical practice in the United States
- (2015) Michael K Wong et al. EXPERT OPINION ON PHARMACOTHERAPY
- Nivolumab for Metastatic Renal Cell Carcinoma: Results of a Randomized Phase II Trial
- (2015) Robert J. Motzer et al. JOURNAL OF CLINICAL ONCOLOGY
- Lenvatinib, everolimus, and the combination in patients with metastatic renal cell carcinoma: a randomised, phase 2, open-label, multicentre trial
- (2015) Robert J Motzer et al. LANCET ONCOLOGY
- Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma
- (2015) Robert J. Motzer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
- (2014) B. Escudier et al. ANNALS OF ONCOLOGY
- SEOM clinical guidelines for the treatment of renal cell carcinoma
- (2014) J. Bellmunt et al. Clinical & Translational Oncology
- Clinical outcomes in patients with metastatic renal cell carcinoma receiving everolimus or temsirolimus after sunitinib.
- (2014) Roberto Iacovelli et al. CUAJ-Canadian Urological Association Journal
- Comparative effectiveness of second-line targeted therapies for metastatic renal cell carcinoma: synthesis of findings from two multi-practice chart reviews in the United States
- (2014) James E. Signorovitch et al. CURRENT MEDICAL RESEARCH AND OPINION
- Drug-induced pneumonitis in cancer patients treated with mTOR inhibitors: management and insights into possible mechanisms
- (2014) Ignacio Duran et al. Expert Opinion On Drug Safety
- Phase II Randomized Trial Comparing Sequential First-Line Everolimus and Second-Line Sunitinib Versus First-Line Sunitinib and Second-Line Everolimus in Patients With Metastatic Renal Cell Carcinoma
- (2014) Robert J. Motzer et al. JOURNAL OF CLINICAL ONCOLOGY
- Comparative Effectiveness of Second-Line Targeted Therapies for Metastatic Renal Cell Carcinoma: A Systematic Review and Meta-Analysis of Real-World Observational Studies
- (2014) Daniel Y. Heng et al. PLoS One
- Anti-programmed death-1 and anti-programmed death-ligand 1 antibodies in cancer therapy
- (2013) Omid Hamid et al. EXPERT OPINION ON BIOLOGICAL THERAPY
- Randomized Phase III Trial of Temsirolimus Versus Sorafenib As Second-Line Therapy After Sunitinib in Patients With Metastatic Renal Cell Carcinoma
- (2013) Thomas E. Hutson et al. JOURNAL OF CLINICAL ONCOLOGY
- Emerging immunotherapies for renal cell carcinoma
- (2012) B. Escudier ANNALS OF ONCOLOGY
- Sequential therapy with targeted agents in patients with advanced renal cell carcinoma: Optimizing patient benefit
- (2012) Stéphane Oudard et al. CANCER TREATMENT REVIEWS
- mTOR Signaling in Growth Control and Disease
- (2012) Mathieu Laplante et al. CELL
- Hallmarks of Cancer: The Next Generation
- (2011) Douglas Hanahan et al. CELL
- An international expanded-access programme of everolimus: Addressing safety and efficacy in patients with metastatic renal cell carcinoma who progress after initial vascular endothelial growth factor receptor-tyrosine kinase inhibitor therapy
- (2011) Viktor Grünwald et al. EUROPEAN JOURNAL OF CANCER
- Everolimus in metastatic renal cell carcinoma: Subgroup analysis of patients with 1 or 2 previous vascular endothelial growth factor receptor-tyrosine kinase inhibitor therapies enrolled in the phase III RECORD-1 study
- (2011) E. Calvo et al. EUROPEAN JOURNAL OF CANCER
- Optimizing treatment of metastatic renal cell carcinoma by changing mechanism of action
- (2011) James Larkin et al. Expert Review of Anticancer Therapy
- Drug-Related Pneumonitis in Patients With Advanced Renal Cell Carcinoma Treated With Temsirolimus
- (2011) Jose Pablo Maroto et al. JOURNAL OF CLINICAL ONCOLOGY
- Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial
- (2011) Brian I Rini et al. LANCET
- Treatment-Associated Adverse Event Management in the Advanced Renal Cell Carcinoma Patient Treated with Targeted Therapies
- (2011) A. Ravaud ONCOLOGIST
- Noninfectious Pneumonitis after Everolimus Therapy for Advanced Renal Cell Carcinoma
- (2010) Dorothy A. White et al. AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE
- Emergent toxicities associated with the use of mTOR inhibitors in patients with advanced renal carcinoma
- (2010) Jesus Rodriguez-Pascual et al. ANTI-CANCER DRUGS
- Phase 3 trial of everolimus for metastatic renal cell carcinoma
- (2010) Robert J. Motzer et al. CANCER
- Mechanisms of resistance to antiangiogenesis therapy
- (2010) Faisal Azam et al. EUROPEAN JOURNAL OF CANCER
- Pazopanib in Locally Advanced or Metastatic Renal Cell Carcinoma: Results of a Randomized Phase III Trial
- (2010) Cora N. Sternberg et al. JOURNAL OF CLINICAL ONCOLOGY
- EORTC-GU group expert opinion on metastatic renal cell cancer
- (2009) Theo M. de Reijke et al. EUROPEAN JOURNAL OF CANCER
- Temsirolimus safety profile and management of toxic effects in patients with advanced renal cell carcinoma and poor prognostic features
- (2008) J. Bellmunt et al. ANNALS OF ONCOLOGY
- Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial
- (2008) Robert J Motzer et al. LANCET
- Tumor Angiogenesis
- (2008) Robert S. Kerbel NEW ENGLAND JOURNAL OF MEDICINE
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationFind the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
Search